Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria

Affiliations

¹ Multiple Sclerosis Center, Department of Neurology, Heinrich-Heine-Universität Düsseldorf, 40225 Düsseldorf, Germany. hans-peter.hartung@uni-duesseldorf.de

Comment

Hans-Peter Hartung et al. Lancet Neurol. 2011 Apr.

. 2011 Apr;10(4):293-5.

doi: 10.1016/S1474-4422(11)70043-6.

¹ Multiple Sclerosis Center, Department of Neurology, Heinrich-Heine-Universität Düsseldorf, 40225 Düsseldorf, Germany. hans-peter.hartung@uni-duesseldorf.de

No abstract available

Comment on

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S; CLARITY study group. Giovannoni G, et al. Lancet Neurol. 2011 Apr;10(4):329-37. doi: 10.1016/S1474-4422(11)70023-0. Lancet Neurol. 2011. PMID: 21397565
Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Coles AJ, et al. Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5. Lancet Neurol. 2011. PMID: 21397567 Clinical Trial.